drugset / Trial / NCT03250325
Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma
NaSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide pre-treatment.
Timeline
- Start
- 2017-09-20
- Primary completion
- 2020-01-23
- Completion
- 2022-03-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TBI-1301 | Cell therapy | 5e+09 cells | — |
| Background | Cyclophosphamide | Other / unclassified | 750 mg/m2 | Intravenous |